Published in TB and Outbreaks Week, October 3rd, 2000
For patients receiving more than seven days of therapy, the response rate was 49% (22 of 45). Cancidas is an echinocandin known as a glucan synthesis inhibitor that is being developed by Merck & Co., Inc. (MRK) to treat serious fungal infections in adults.
The study was presented at the 40th Annual Meeting of the Interscience Conference on Antimicrobial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week